\u7d50\u679c<\/strong><\/p>\n<\/td>\n| \n \u5168\u4f53\u3067\u3001\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3Lp(a)\u4e2d\u592e\u5024\u306f42.9 nmol\/L\u3067\u3042\u308a\u3001448\u4f8b\uff0819.0%\uff09\u304c50\u301c150 nmol\/L\u3001665\u4f8b\uff0828.2%\uff09\u304c150 nmol\/L\u4ee5\u4e0a\u3067\u3042\u3063\u305f\u3002\u30b3\u30db\u30fc\u30c8\u5168\u4f53\u3067\u306f\u3001obicetrapib\u306f12\u9031\u6642\u70b9\u3067Lp(a)\u309237.3%\uff08\u30d7\u30e9\u30bb\u30dc\u88dc\u6b63\uff09\u4f4e\u4e0b\u3055\u305b\u3001\u7d76\u5bfe\u4f4e\u4e0b\u91cf\u306f14.9 nmol\/L\u3067\u3042\u3063\u305f\uff08p<0.0001\uff09\uff08\u88681\uff09\u3002Obicetrapib\u306b\u3088\u308bLp(a)\u4f4e\u4e0b\u7387\u306f\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3Lp(a)\u5024\u306b\u3088\u308a\u6709\u610f\u306a\u7570\u8cea\u6027\u304c\u307f\u3089\u308c\u305f\u3082\u306e\u306e\u3001\u30d7\u30e9\u30bb\u30dc\u88dc\u6b63\u5f8c\u306e\u7d76\u5bfe\u4f4e\u4e0b\u91cf\u306f\u540c\u7a0b\u5ea6\u3067\u3042\u3063\u305f\uff08\u88681\uff09\u3002\u4e00\u65b9\u3001obicetrapib\u306b\u3088\u308bLDL-C\u306e\u7d76\u5bfe\u304a\u3088\u3073\u30d7\u30e9\u30bb\u30dc\u88dc\u6b63\u5f8c\u306e\u4f4e\u4e0b\u7387\u306f\u3001\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3Lp(a)\u5024\u304c\u7570\u306a\u308b\u60a3\u8005\u9593\u3067\u4e00\u8cab\u3057\u3066\u3044\u305f\u3002 <\/p>\n <\/p>\n \u88681<\/strong>\uff0e\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3Lp(a)\u30ab\u30c6\u30b4\u30ea\u30fc\u5225\u306e\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u304a\u3088\u307312\u9031\u6642\u70b9\u306e\u30ea\u30dd\u30d7\u30ed\u30c6\u30a4\u30f3 <\/p>\n\n\n\n| \n \u30d9\u30fc\u30b9\u30e9\u30a4\u30f3Lp(a)<\/p>\n<\/td>\n | \n \u30d7\u30e9\u30bb\u30dc<\/p>\n<\/td>\n | \n Obicetrapib<\/p>\n<\/td>\n | \n \u30d7\u30e9\u30bb\u30dc\u88dc\u6b63<\/p>\n<\/td>\n | \n p\u5024<\/p>\n<\/td>\n<\/tr>\n | \n| \n <50 nmol\/L<\/strong><\/p>\n<\/td>\n| \n N=501<\/p>\n<\/td>\n | \n N=742<\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n<\/tr>\n | \n| \n Baseline, nmol\/L<\/p>\n<\/td>\n | \n 13.5 (5.7,24.8)<\/p>\n<\/td>\n | \n 13.5 (5.3, 24.4)<\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n<\/tr>\n | \n| \n Week 12, nmol\/L<\/p>\n<\/td>\n | \n 12.5 (5.6,24.7)<\/p>\n<\/td>\n | \n 5.0 (2.8, 10.8)<\/p>\n<\/td>\n | \n -6.1<\/p>\n (\u22127.2, \u22124.9)<\/p>\n<\/td>\n | \n <0.0001<\/p>\n<\/td>\n<\/tr>\n | \n| \n Absolute change, nmol\/L<\/p>\n<\/td>\n | \n 0 (\u22122.0, 2.2)<\/p>\n<\/td>\n | \n -5.0<\/p>\n (\u221213.4, \u22121.6)<\/p>\n<\/td>\n | \n -6.2<\/p>\n (\u22127.0, \u22125.3)<\/p>\n<\/td>\n | \n <0.0001<\/p>\n<\/td>\n<\/tr>\n | \n| \n \u5909\u5316\u7387<\/p>\n<\/td>\n | \n 0 (\u221218.1, 22.6)<\/p>\n<\/td>\n | \n -52.4<\/p>\n (\u221270.8, \u221218.0)<\/p>\n<\/td>\n | \n -50.9<\/p>\n (\u221254.8, \u221247.1)<\/p>\n<\/td>\n | \n <0.0001<\/p>\n<\/td>\n<\/tr>\n | \n| \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n<\/tr>\n | \n| \n 50 to <150 nmol\/L<\/strong><\/p>\n<\/td>\n| \n N=170<\/p>\n<\/td>\n | \n N=278<\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n<\/tr>\n | \n| \n Baseline, nmol\/L<\/p>\n<\/td>\n | \n 94.2<\/p>\n (67.3, 117.4)<\/p>\n<\/td>\n | \n 89.2<\/p>\n (66.8, 116.9)<\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n<\/tr>\n | \n| \n Week 12, nmol\/L<\/p>\n<\/td>\n | \n 92.5<\/p>\n (62.5, 121.5)<\/p>\n<\/td>\n | \n 44.8<\/p>\n (20.9, 83.7)<\/p>\n<\/td>\n | \n -38.7<\/p>\n (\u221246.0, \u221231.4)<\/p>\n<\/td>\n | \n <0.0001<\/p>\n<\/td>\n<\/tr>\n | \n| \n Absolute change, nmol\/L<\/p>\n<\/td>\n | \n -4.5 (\u221212.3, 8.8)<\/p>\n<\/td>\n | \n -39.5<\/p>\n (\u221257.2, \u221218.1)<\/p>\n<\/td>\n | \n -36.3<\/p>\n (\u221241.2, \u221231.4)<\/p>\n<\/td>\n | \n <0.0001<\/p>\n<\/td>\n<\/tr>\n | \n| \n \u5909\u5316\u7387<\/p>\n<\/td>\n | \n -4.1<\/p>\n (\u221216.3, 10.0)<\/p>\n<\/td>\n | \n -46.3<\/p>\n (\u221271.1, \u221221.5)<\/p>\n<\/td>\n | \n -43.3<\/p>\n (\u221249.5, \u221237.1)<\/p>\n<\/td>\n | \n <0.0001<\/p>\n<\/td>\n<\/tr>\n | \n| \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n<\/tr>\n | \n| \n \u2265150 nmol\/L<\/strong><\/p>\n<\/td>\n| \n N=249<\/p>\n<\/td>\n | \n N=416<\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n<\/tr>\n | \n| \n Baseline, nmol\/L<\/p>\n<\/td>\n | \n 249.6<\/p>\n (197.5, 341.0)<\/p>\n<\/td>\n | \n 249.0<\/p>\n (200.3, 347.2)<\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n | \n <\/p>\n<\/td>\n<\/tr>\n | \n| \n Week 12, nmol\/L<\/p>\n<\/td>\n | \n 251.6<\/p>\n (191.8, 331.8)<\/p>\n<\/td>\n | \n 225.0<\/p>\n (161.3, 315.6)<\/p>\n<\/td>\n | \n -31.4<\/p>\n (\u221248.2, \u221214.6)<\/p>\n<\/td>\n | \n 0.003<\/p>\n<\/td>\n<\/tr>\n | \n| \n Absolute change, nmol\/L<\/p>\n<\/td>\n | \n -2.5<\/p>\n (\u221225.6, 20.7)<\/p>\n<\/td>\n | \n -31.8<\/p>\n (\u221277.8, 2.2)<\/p>\n<\/td>\n | \n -32.3<\/p>\n (\u221240.5, \u221224.1)<\/p>\n<\/td>\n | \n <0.0001<\/p>\n<\/td>\n<\/tr>\n | \n| \n \u5909\u5316\u7387<\/p>\n<\/td>\n | \n -1.3 (\u22129.5, 8.8)<\/p>\n<\/td>\n | \n -13.3<\/p>\n (\u221227.7, 0.8)<\/p>\n<\/td>\n | \n -12.6<\/p>\n (\u221215.6, \u22129.6)<\/p>\n<\/td>\n | \n <0.0001<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n \u30c7\u30fc\u30bf\u306f\u5404\u6cbb\u7642\u7fa4\u306b\u3064\u3044\u3066\u4e2d\u592e\u5024\uff08\u56db\u5206\u4f4d\u7bc4\u56f2\uff09\u3067\u793a\u3057\u3001\u30d7\u30e9\u30bb\u30dc\u88dc\u6b63\u5f8c\u306e\u5dee\u306fLp(a)\u30ab\u30c6\u30b4\u30ea\u30fc\u306b\u3088\u308b\u5c64\u5225\u5316\u3092\u53cd\u6620\u3057\u305f2\u6a19\u672cHodges-Lehmann\u6cd5\u306b\u3088\u308b\u5dee\u306e\u4e2d\u592e\u5024\u306e95%\u4fe1\u983c\u533a\u9593\u4e2d\u70b9\u3067\u793a\u3057\u305f\u3002<\/p>\n <\/p>\n \u30d7\u30e9\u30bb\u30dc\u3068\u6bd4\u8f03\u3057\u3066\u3001obicetrapib\u6295\u4e0e\u7fa4\u3067\u306f\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u304b\u3089Lp(a)\u304c>50%\u3092\u8d85\u3048\u3066\u4f4e\u4e0b\u3057\u305f\u60a3\u8005\u306e\u5272\u5408\u304c\u9ad8\u304b\u3063\u305f\uff0838.4% vs \u30d7\u30e9\u30bb\u30dc3.0%\u3001p<<0.0001\uff09\u3002\u3055\u3089\u306b\u3001obicetrapib\u6295\u4e0e\u60a3\u8005\u306f\u3001Lp(a)\u306e >50% and an on-treatment LDL-C <40 mg\/dL (12.0% vs 0% on placebo, p <0.0001), <55 mg\/dL (21.7% vs 0.5%, p <0.0001) and <70 mg\/dL (27.4% vs 1.2%, p <0.0001).<\/p>\n <\/p>\n<\/td>\n<\/tr>\n | \n| \n \u8457\u8005\u306e\u7d50\u8ad6<\/strong><\/p>\n<\/td>\n| \n Obicetrapib\u306fLDL-C\u3001apoB\u304a\u3088\u3073Lp(a)\u3092\u4f4e\u4e0b\u3055\u305b\u305f\u3002\u8efd\u5ea6\u306eLp(a)\u4e0a\u6607\u3092\u793a\u3059\u60a3\u8005\u3067\u306fRNA\u6a19\u7684Lp(a)\u4f4e\u4e0b\u85ac\u306e\u9069\u5fdc\u3068\u306a\u308a\u306b\u304f\u3044\u304c\u3001\u3053\u3046\u3057\u305f\u60a3\u8005\u306b\u304a\u3044\u3066\u3082obicetrapib\u306b\u3088\u308bLp(a)\u306e\u7d76\u5bfe\u4f4e\u4e0b\u91cf\u306f\u540c\u7a0b\u5ea6\u3067\u3042\u3063\u305f\u3002 <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n <\/strong><\/p>\n\u30b3\u30e1\u30f3\u30c8<\/strong><\/p>\nObicetrapib\u306fLDL-C\u3092\u4f4e\u4e0b\u3055\u305b\u3001\u9ad8\u6bd4\u91cd\u30ea\u30dd\u86cb\u767d\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\uff08HDL-C\uff09\u3092\u4e0a\u6607\u3055\u305b\u308b\u52b9\u679c\u304c\u78ba\u8a8d\u3055\u308c\u3066\u3044\u308b\uff081,2\uff09\u3002\u4eca\u56de\u306e\u30d7\u30fc\u30eb\u89e3\u6790\u306f\u8102\u8cea\u8abf\u7bc0\u4f5c\u7528\u306e\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3092\u3055\u3089\u306b\u5e83\u3052\u308b\u3082\u306e\u3067\u3042\u308a\u3001\u5168\u4f53\u3067Lp(a)\u309237%\u4f4e\u4e0b\u3055\u305b\u3001\u305d\u306e\u52b9\u679c\u306fLp(a)\u6fc3\u5ea6\u306e\u7bc4\u56f2\u5168\u4f53\u3067\u304a\u304a\u3080\u306d\u4e00\u8cab\u3057\u3066\u3044\u305f\u3002 <\/p>\n <\/p>\n \u3053\u308c\u3089\u306e\u77e5\u898b\u306f\u3001\u9ad8Lp(a)\u8840\u75c7\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u9078\u629e\u80a2\u304c\u3053\u308c\u307e\u3067\u9650\u3089\u308c\u3066\u3044\u308b\u3053\u3068\u3092\u8e0f\u307e\u3048\u308b\u3068\u91cd\u8981\u3067\u3042\u308b\u3002PCSK9\u963b\u5bb3\u85ac\u306f\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u5024\u304c\u9ad8\u3044\u60a3\u8005\u306b\u304a\u3044\u3066LDL-C\u4f4e\u4e0b\u306e\u7a0b\u5ea6\u3068\u306f\u72ec\u7acb\u3057\u3066Lp(a)\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u304c\uff083,4\uff09\u3001\u305d\u306e\u52b9\u679c\u306f\u8efd\u5ea6\u306b\u3068\u3069\u307e\u308b\u305f\u3081\u3001Lp(a)\u3092\u7279\u7570\u7684\u306b\u4f4e\u4e0b\u3055\u305b\u308b\u65b0\u898f\u6cbb\u7642\u306e\u63a2\u7d22\u304c\u9032\u3081\u3089\u308c\u3066\u304d\u305f\u3002\u73fe\u5728\u3001\u30a2\u30f3\u30c1\u30bb\u30f3\u30b9\u30aa\u30ea\u30b4\u30cc\u30af\u30ec\u30aa\u30c1\u30c9\uff08ASO\uff09\u3001siRNA\u88fd\u5264\u3001\u4f4e\u5206\u5b50\u963b\u5bb3\u85ac\u306a\u3069\u8907\u6570\u304c\u81e8\u5e8a\u958b\u767a\u4e2d\u3067\u3042\u308b\u3002\u3053\u308c\u3089\u306fLp(a)\u304c\u9ad8\u5024\u304b\u3089\u8457\u660e\u9ad8\u5024\u306e\u60a3\u8005\u306b\u304a\u3044\u3066\u9ad8\u3044\u6709\u52b9\u6027\u3092\u793a\u3057\u3001\u5c11\u306a\u304f\u3068\u308280%\u3001\u6700\u592795%\u306b\u53ca\u3076\u4f4e\u4e0b\u3092\u9054\u6210\u3057\u3066\u3044\u308b\uff085-12\uff09\u3002\u3057\u304b\u3057\u3001\u898f\u5236\u5f53\u5c40\u306e\u627f\u8a8d\u3092\u524d\u63d0\u3068\u3057\u3066\u3082\u3001\u3053\u308c\u3089\u65b0\u898f\u85ac\u5264\u3092\u5b9f\u5730\u8a3a\u7642\u306b\u53d6\u308a\u5165\u308c\u308b\u969b\u306b\u306f\u3001\u6295\u4e0e\u7d4c\u8def\uff08\u6ce8\u5c04\uff09\u3068\u8cbb\u7528\u306e\u9762\u3067\u5b9f\u969b\u7684\u306a\u5236\u7d04\u304c\u751f\u3058\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u3002\u3055\u3089\u306b\u3001\u9032\u884c\u4e2d\u306e\u5927\u898f\u6a21\u30a2\u30a6\u30c8\u30ab\u30e0\u8a66\u9a13\u3067\u306fLp(a)\u306e\u9078\u629e\u57fa\u6e96\u304c\u975e\u5e38\u306b\u9ad8\u304f\u8a2d\u5b9a\u3055\u308c\u3066\u3044\u308b\uff08ASO\u306epelacarsen\u3067\u306f>>70 mg\/dL\u307e\u305f\u306f\u7d04>175 nmol\/L\u3001siRNA\u88fd\u5264\u306elepodisiran\u304a\u3088\u3073olpasiran\u3067\u306f\u305d\u308c\u305e\u308c>175 nmol\/L\u304a\u3088\u3073200 nmol\/L\uff09\u3002 <\/p>\n <\/p>\n \u7279\u5b9a\u306e\u7ba1\u7406\u76ee\u6a19\u5024\u306f\u306a\u3044\u3082\u306e\u306e\u3001\u73fe\u884c\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3067\u306fLp(a)>>125 nmol\/L\u304c\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u4e0a\u6607\u3068\u95a2\u9023\u3059\u308b\u3068\u3055\u308c\u3066\u3044\u308b\uff0813,14\uff09\u3002\u8a66\u9a13\u306e\u9078\u629e\u57fa\u6e96\u306b\u5b9a\u3081\u3089\u308c\u305f\u5024\u3092\u8003\u616e\u3059\u308b\u3068\u3001Lp(a)\u304c\u4e2d\u7b49\u5ea6\u306b\u4e0a\u6607\u3057\u3066\u3044\u308b\u60a3\u8005\u306e\u5927\u534a\u306f\u3001\u3053\u308c\u3089\u306e\u9ad8\u5ea6\u306b\u7279\u7570\u7684\u306a\u6cbb\u7642\u304c\u5229\u7528\u53ef\u80fd\u306b\u306a\u3063\u3066\u3082\u53d7\u3051\u3089\u308c\u305a\u3001\u9ad8\u3044\u6b8b\u4f59\u30ea\u30b9\u30af\u3092\u62b1\u3048\u305f\u307e\u307e\u3068\u306a\u308b\u3002\u73fe\u5728\u3001Lp(a)\u6fc3\u5ea6\u3068ASCVD\u3068\u306e\u9593\u306b\u9023\u7d9a\u7684\u306a\u95a2\u9023\u304c\u3042\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u3066\u3044\u308b\uff0815\uff09\u3053\u3068\u304b\u3089\u3001\u3053\u3046\u3057\u305f\u60a3\u8005\u304c\u5229\u7528\u3067\u304d\u308b\u5225\u306e\u6cbb\u7642\u306e\u5fc5\u8981\u6027\u306f\u660e\u3089\u304b\u3067\u3042\u308b\u3002 <\/p>\n <\/p>\n \u4eca\u56de\u306e\u89e3\u6790\u3067\u306f\u3001obicetrapib\u304cLDL-C\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u3060\u3051\u3067\u306a\u304f\u3001Lp(a)\u304c\u4e2d\u7b49\u5ea6\u306b\u4e0a\u6607\u3057\u3066\u3044\u308b\u306b\u3068\u3069\u307e\u308b\u60a3\u8005\u306b\u304a\u3044\u3066\u3082Lp(a)\u3092\u6709\u52b9\u306b\u4f4e\u4e0b\u3055\u305b\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f\u3002Obicetrapib\u306eLp(a)\u4f4e\u4e0b\u4f5c\u7528\u306fLDL-C\u3078\u306e\u5f71\u97ff\u3068\u306f\u72ec\u7acb\u3057\u3066\u3044\u305f\u3002\u3057\u305f\u304c\u3063\u3066obicetrapib\u306f\u3001\u7d4c\u53e3\u85ac\u3068\u3044\u3046\u5b9f\u969b\u7684\u306a\u5229\u70b9\u3092\u5099\u3048\u3064\u3064\u3001\u3053\u3046\u3057\u305f\u60a3\u8005\u306b\u304a\u3051\u308bLp(a)\u95a2\u9023\u306e\u6b8b\u4f59\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u3092\u4f4e\u6e1b\u3059\u308b\u53ef\u80fd\u6027\u3092\u6709\u3059\u308b\u3002 <\/p>\n <\/p>\n \u53c2\u8003\u6587\u732e<\/strong><\/p>\n\n- Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med 2022;28:1672\u20138. <\/li>\n
- Ballantyne CM, Ditmarsch M, Kastelein JJ, et al. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial. J Clin Lipidol 2023;17:491\u2013503. <\/li>\n
- O\u2019Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 2019;139:1483\u201392. <\/li>\n
- Szarek M, Bittner VA, Aylward P, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J 2020;41:4245\u201355. <\/li>\n
- Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. \u5fc3\u8840\u7ba1\u75be\u60a3\u60a3\u8005\u306b\u304a\u3051\u308b\u30ea\u30dd\u86cb\u767d\uff08a\uff09\u306e\u6e1b\u5c11\u3002N Engl J Med 2020;382:244-55. <\/li>\n
- Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015;386:1472\u201383. <\/li>\n
- Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA 2022;327:1679\u201387. <\/li>\n
- O\u2019Donoghue ML, Rosenson RS, Lopez JAG, et al. The off-treatment effects of olpasiran on lipoprotein(a) lowering: OCEAN(a)-dose extension period results. J Am Coll Cardiol 2024;84:790\u20137. <\/li>\n
- Nissen SE, Linnebjerg H, Shen X, et al. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial. JAMA 2023;330:2075\u201383. <\/li>\n
- Nissen SE, Ni W, Shen X, et al. Lepodisiran \u2013 A long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med 2025;392:1145\u201355. <\/li>\n
- Nissen SE, Wolski K, Watts GF, et al. Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial. JAMA 2024;331:1534\u201343. <\/li>\n
- Nicholls SJ, Ni W, Rhodes GM, et al. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA 2025;333:222\u201331. <\/li>\n
- \u8102\u8cea\u7570\u5e38\u75c7\u7ba1\u7406\u306e\u305f\u3081\u306e2019\u5e74ESC\/EAS\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\uff1a\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u4f4e\u6e1b\u306e\u305f\u3081\u306e\u8102\u8cea\u4fee\u98fe\u3002Eur Heart J 2020;41:111-88. <\/li>\n
- Blumenthal RS, Morris PB, Gaudino M, et al. ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87:2624\u2013757. <\/li>\n
- \u30a2\u30c6\u30ed\u30fc\u30e0\u6027\u52d5\u8108\u786c\u5316\u6027\u5fc3\u8840\u7ba1\u75be\u60a3\u3068\u5927\u52d5\u8108\u5f01\u72ed\u7a84\u75c7\u306b\u304a\u3051\u308b\u30ea\u30dd\u86cb\u767d\uff08a\uff09\uff1a\u6b27\u5dde\u52d5\u8108\u786c\u5316\u5b66\u4f1a\u306e\u30b3\u30f3\u30bb\u30f3\u30b5\u30b9\u30fb\u30b9\u30c6\u30fc\u30c8\u30e1\u30f3\u30c8\u3002Eur Heart J 2022;43:3925-46. <\/li>\n<\/ol>\n
Key words: Lipoprotein(a); Lp(a); obicetrapib; residual cardiovascular risk; BROOKLYN, BROADWAY<\/em><\/p>\n<\/div>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Obicetrapib\u304c\u30ea\u30dd\u30d7\u30ed\u30c6\u30a4\u30f3(a)\u4f4e\u4e0b\u4f5c\u7528\u3092\u793a\u3059 2026\u5e749\u6708 \u30b3\u30ec\u30b9\u30c6\u30ea\u30eb\u30a8\u30b9\u30c6\u30eb\u8ee2\u9001\u86cb\u767d\uff08CE […]<\/p>\n","protected":false},"author":258497324,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_wpcom_ai_launchpad_about_page":false,"_wpcom_ai_launchpad_gallery_page":false,"_wpcom_ai_launchpad_contact_page":false,"_wpcom_ai_launchpad_events_page":false,"_wpcom_ai_launchpad_video_page":false,"_wpcom_ai_launchpad_portfolio_piece":false,"footnotes":""},"class_list":["post-258017","page","type-page","status-publish","hentry"],"yoast_head":"\n Focus \u2013 Obicetrapib\u304c\u30ea\u30dd\u30d7\u30ed\u30c6\u30a4\u30f3(a)\u4f4e\u4e0b\u4f5c\u7528\u3092\u793a\u3059 - R3I<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/r3i.org\/ja\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Focus \u2013 Obicetrapib\u304c\u30ea\u30dd\u30d7\u30ed\u30c6\u30a4\u30f3(a)\u4f4e\u4e0b\u4f5c\u7528\u3092\u793a\u3059 - R3I\" \/>\n<meta property=\"og:description\" content=\"Obicetrapib\u304c\u30ea\u30dd\u30d7\u30ed\u30c6\u30a4\u30f3(a)\u4f4e\u4e0b\u4f5c\u7528\u3092\u793a\u3059 2026\u5e749\u6708 \u30b3\u30ec\u30b9\u30c6\u30ea\u30eb\u30a8\u30b9\u30c6\u30eb\u8ee2\u9001\u86cb\u767d\uff08CE […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/r3i.org\/ja\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\/\" \/>\n<meta property=\"og:site_name\" content=\"R3I\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-30T21:20:32+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data1\" content=\"4\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\\\/\",\"url\":\"https:\\\/\\\/r3i.org\\\/ja\\\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\\\/\",\"name\":\"Focus \u2013 Obicetrapib\u304c\u30ea\u30dd\u30d7\u30ed\u30c6\u30a4\u30f3(a)\u4f4e\u4e0b\u4f5c\u7528\u3092\u793a\u3059 - R3I\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/#website\"},\"datePublished\":\"2026-08-30T20:53:18+00:00\",\"dateModified\":\"2026-08-30T21:20:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/r3i.org\\\/ja\\\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/r3i.org\\\/ja\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Focus \u2013 Obicetrapib\u304c\u30ea\u30dd\u30d7\u30ed\u30c6\u30a4\u30f3(a)\u4f4e\u4e0b\u4f5c\u7528\u3092\u793a\u3059\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/#website\",\"url\":\"https:\\\/\\\/r3i.org\\\/ja\\\/\",\"name\":\"R3I\",\"description\":\"Residual Risk Reduction Initiative\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/r3i.org\\\/ja\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Focus \u2013 Obicetrapib\u304c\u30ea\u30dd\u30d7\u30ed\u30c6\u30a4\u30f3(a)\u4f4e\u4e0b\u4f5c\u7528\u3092\u793a\u3059 - R3I","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/r3i.org\/ja\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\/","og_locale":"ja_JP","og_type":"article","og_title":"Focus \u2013 Obicetrapib\u304c\u30ea\u30dd\u30d7\u30ed\u30c6\u30a4\u30f3(a)\u4f4e\u4e0b\u4f5c\u7528\u3092\u793a\u3059 - R3I","og_description":"Obicetrapib\u304c\u30ea\u30dd\u30d7\u30ed\u30c6\u30a4\u30f3(a)\u4f4e\u4e0b\u4f5c\u7528\u3092\u793a\u3059 2026\u5e749\u6708 \u30b3\u30ec\u30b9\u30c6\u30ea\u30eb\u30a8\u30b9\u30c6\u30eb\u8ee2\u9001\u86cb\u767d\uff08CE […]","og_url":"https:\/\/r3i.org\/ja\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\/","og_site_name":"R3I","article_modified_time":"2026-08-30T21:20:32+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/r3i.org\/ja\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\/","url":"https:\/\/r3i.org\/ja\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\/","name":"Focus \u2013 Obicetrapib\u304c\u30ea\u30dd\u30d7\u30ed\u30c6\u30a4\u30f3(a)\u4f4e\u4e0b\u4f5c\u7528\u3092\u793a\u3059 - R3I","isPartOf":{"@id":"https:\/\/r3i.org\/ja\/#website"},"datePublished":"2026-08-30T20:53:18+00:00","dateModified":"2026-08-30T21:20:32+00:00","breadcrumb":{"@id":"https:\/\/r3i.org\/ja\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/r3i.org\/ja\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/r3i.org\/ja\/focus-obicetrapib%e3%81%8c%e3%83%aa%e3%83%9d%e3%83%97%e3%83%ad%e3%83%86%e3%82%a4%e3%83%b3a%e4%bd%8e%e4%b8%8b%e4%bd%9c%e7%94%a8%e3%82%92%e7%a4%ba%e3%81%99\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/r3i.org\/ja\/"},{"@type":"ListItem","position":2,"name":"Focus \u2013 Obicetrapib\u304c\u30ea\u30dd\u30d7\u30ed\u30c6\u30a4\u30f3(a)\u4f4e\u4e0b\u4f5c\u7528\u3092\u793a\u3059"}]},{"@type":"WebSite","@id":"https:\/\/r3i.org\/ja\/#website","url":"https:\/\/r3i.org\/ja\/","name":"R3I","description":"Residual Risk Reduction Initiative","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/r3i.org\/ja\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"}]}},"jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/Pgbfv2-157z","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/258017","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/users\/258497324"}],"replies":[{"embeddable":true,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/comments?post=258017"}],"version-history":[{"count":2,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/258017\/revisions"}],"predecessor-version":[{"id":258019,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/258017\/revisions\/258019"}],"wp:attachment":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/media?parent=258017"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} | | | | | |